The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
Oo
Charles
C
Chen
Ya-Chi
YC
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D065692:Cytochrome P-450 CYP3A Inhibitors; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology*; D017410:Practice Guidelines as Topic; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000935:Antifungal Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D007654:Ketoconazole